444 related articles for article (PubMed ID: 29880308)
1. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
[TBL] [Abstract][Full Text] [Related]
2. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
[TBL] [Abstract][Full Text] [Related]
3. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
[TBL] [Abstract][Full Text] [Related]
4. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
[TBL] [Abstract][Full Text] [Related]
5. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
[TBL] [Abstract][Full Text] [Related]
6. Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated
Bowman P; Mathews F; Barbetti F; Shepherd MH; Sanchez J; Piccini B; Beltrand J; Letourneau-Freiberg LR; Polak M; Greeley SAW; Rawlins E; Babiker T; Thomas NJ; De Franco E; Ellard S; Flanagan SE; Hattersley AT;
Diabetes Care; 2021 Jan; 44(1):35-42. PubMed ID: 33184150
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected].
Busiah K; Drunat S; Vaivre-Douret L; Bonnefond A; Simon A; Flechtner I; Gérard B; Pouvreau N; Elie C; Nimri R; De Vries L; Tubiana-Rufi N; Metz C; Bertrand AM; Nivot-Adamiak S; de Kerdanet M; Stuckens C; Jennane F; Souchon PF; Le Tallec C; Désirée C; Pereira S; Dechaume A; Robert JJ; Phillip M; Scharfmann R; Czernichow P; Froguel P; Vaxillaire M; Polak M; Cavé H;
Lancet Diabetes Endocrinol; 2013 Nov; 1(3):199-207. PubMed ID: 24622368
[TBL] [Abstract][Full Text] [Related]
9. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
[TBL] [Abstract][Full Text] [Related]
10. Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures.
Lanning MS; Carmody D; Szczerbiński Ł; Letourneau LR; Naylor RN; Greeley SAW
Pediatr Diabetes; 2018 May; 19(3):393-397. PubMed ID: 29205704
[TBL] [Abstract][Full Text] [Related]
11. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.
Vendramini MF; Gurgel LC; Moisés RS
Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):682-4. PubMed ID: 21340152
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation and long-term outcome of patients with KCNJ11/ABCC8 variants: Neonatal diabetes or MODY in the DPV registry from Germany and Austria.
Warncke K; Eckert A; Kapellen T; Kummer S; Raile K; Dunstheimer D; Grulich-Henn J; Woelfle J; Wenzel S; Hofer SE; Dost A; Holl RW
Pediatr Diabetes; 2022 Nov; 23(7):999-1008. PubMed ID: 35822653
[TBL] [Abstract][Full Text] [Related]
13. Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.
Garcin L; Mericq V; Fauret-Amsellem AL; Cave H; Polak M; Beltrand J
Pediatr Diabetes; 2020 Sep; 21(6):932-941. PubMed ID: 32418263
[TBL] [Abstract][Full Text] [Related]
14. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
[No Abstract] [Full Text] [Related]
15. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
Rafiq M; Flanagan SE; Patch AM; Shields BM; Ellard S; Hattersley AT;
Diabetes Care; 2008 Feb; 31(2):204-9. PubMed ID: 18025408
[TBL] [Abstract][Full Text] [Related]
16. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.
Thurber BW; Carmody D; Tadie EC; Pastore AN; Dickens JT; Wroblewski KE; Naylor RN; Philipson LH; Greeley SA;
Diabetologia; 2015 Jul; 58(7):1430-5. PubMed ID: 25877689
[TBL] [Abstract][Full Text] [Related]
17. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications.
Tammaro P; Flanagan SE; Zadek B; Srinivasan S; Woodhead H; Hameed S; Klimes I; Hattersley AT; Ellard S; Ashcroft FM
Diabetologia; 2008 May; 51(5):802-10. PubMed ID: 18335204
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.
Klupa T; Skupien J; Mirkiewicz-Sieradzka B; Gach A; Noczynska A; Zubkiewicz-Kucharska A; Szalecki M; Kozek E; Nazim J; Mlynarski W; Malecki MT
Diabetes Technol Ther; 2010 May; 12(5):387-91. PubMed ID: 20184447
[TBL] [Abstract][Full Text] [Related]
19. Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient`s follow-up.
Ješić MD; Stock H; Zdravković V; Kovačević S; Savić M; Ješić MM
Turk J Pediatr; 2021; 63(3):490-494. PubMed ID: 34254494
[TBL] [Abstract][Full Text] [Related]
20. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
Abbasi F; Saba S; Ebrahim-Habibi A; Sayahpour FA; Amiri P; Larijani B; Amoli MM
Mol Diagn Ther; 2012 Apr; 16(2):109-14. PubMed ID: 22471336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
